-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MCP64NolI8gvey5JZWZ87kXIGZmWlGjwad/vgkRaUxwTh/D9mXSdMQgaFVJr9cLV 3xxGBzw2RAD7nlyhA/egow== 0000891618-03-002661.txt : 20030521 0000891618-03-002661.hdr.sgml : 20030521 20030521163053 ACCESSION NUMBER: 0000891618-03-002661 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20030520 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20030521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CONNETICS CORP CENTRAL INDEX KEY: 0001004960 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943173928 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27406 FILM NUMBER: 03714764 BUSINESS ADDRESS: STREET 1: 3400 W BAYSHORE RD CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: 4158432800 MAIL ADDRESS: STREET 1: 3400 W BAYSHORE RD CITY: PALO ALTO STATE: CA ZIP: 94303 FORMER COMPANY: FORMER CONFORMED NAME: CONNECTIVE THERAPEUTICS INC DATE OF NAME CHANGE: 19951214 8-K 1 f90441e8vk.htm FORM 8-K Connetics Corporation,Form 8-K, 5/20/2003
Table of Contents

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

May 20, 2003


(Date of earliest event reported)

CONNETICS CORPORATION


(Exact name of Registrant as specified in its charter)
         
Delaware   0-27406   94-3173928

 
 
(State or Other Jurisdiction of Incorporation)   (Commission File No.)   (IRS Employer Identification No.)

3290 West Bayshore Road, Palo Alto, California 94303


(Address of principal executive offices, including zip code)

     (650)  843-2800


     (Registrant’s telephone number, including area code)

 


Item 5. Other Events.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1


Table of Contents

Item 5. Other Events.

     On May 20, 2003, Connetics Corporation announced that it intends to raise approximately $75 million through an offering of five-year notes that are convertible into shares of Connetics common stock, subject to market and other conditions. Connetics may raise up to an additional $10 million upon exercise of an over-allotment option in connection with the offering. A copy of the press release relating to this announcement is attached hereto as Exhibit 99.1 and is incorporated into this report by reference.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

  (c)   Exhibits.

             
  Exhibit No.   Description
 
 
 
  99.1   Press Release dated May 20, 2003.

 


Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

             
            CONNETICS CORPORATION
 
        By:   /s/ John L. Higgins
           
            John L. Higgins
            Executive Vice President, Finance
            and Corporate Development and
            Chief Financial Officer
Date:  May 21, 2003            

 


Table of Contents

EXHIBIT INDEX

             
Exhibit No. Description


99.1 Press Release dated May 20, 2003.

  EX-99.1 3 f90441exv99w1.htm EXHIBIT 99.1 Exhibit 99.1

 

EXHIBIT 99.1

(CONNECTICS L0GO)

     
Company Contact   Investor Relations

 
John Higgins   Ina McGuinness or Bruce Voss
Chief Financial Officer   Lippert/Heilshorn & Associates
(650) 843-2800   (310) 691-7100
jhiggins@connetics.com   imcguinness@lhai.com

CONNETICS TO RAISE $75 MILLION FROM OFFERING OF CONVERTIBLE NOTES

PALO ALTO, Calif. (May xx, 2003) — Connetics Corporation (Nasdaq: CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, today announced that it intends to raise approximately $75 million through an offering of five-year notes that are convertible into shares of Connetics common stock, subject to market and other conditions. The company may raise up to an additional $10 million upon exercise of an over-allotment option in connection with the offering.

Connetics expects to use the proceeds from the offering to augment its cash reserves for general corporate purposes, including potential future product or company acquisitions, capital expenditures and working capital.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities. Any offers of the securities will be made only by means of a private offering circular pursuant to Rule 144A under the Securities Act of 1933, as amended. The securities have not been, and will not be, registered under the Securities Act of 1933, as amended, or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Connetics

Connetics Corporation is an independent pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market. The Company’s marketed products are OLUX® (clobetasol propionate) Foam, 0.05% and Luxiq® (betamethasone valerate) Foam, 0.12%. Connetics’ wholly owned subsidiary, Connetics Australia Pty Ltd., is focused on discovering and developing innovative topical drug delivery formulations. These formulations aim to improve the management of dermatological diseases and provide significant product differentiation. For more information about Connetics and its products, please visit Connetics’ web site at www.connetics.com, or send an email to ir@connetics.com.

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements include, but are not limited to, statements regarding the company’s objective and its intended use of proceeds. These forward-looking statements involve certain

 


 

2

risks and uncertainties that could cause actual results to differ, including, but not limited to, a general downturn in economic conditions, our ability to fund our operations from our revenues, fluctuations in our operating results, risks related to the development and manufacture of our products, competitive pressures, our ability to develop new products and/or integrate them into our business and such other risks as identified in our 10-K/A for the fiscal year ended December 31, 2002, filed with the Securities and Exchange Commission and all subsequent filings with the Securities and Exchange Commission, including our Form 10-Q for the period ended March 31, 2003, which contain and identify important factors that could cause the actual results to differ materially from those contained in our projections or forward-looking statements.

###

  GRAPHIC 4 f90441f9044101.gif GRAPHIC begin 644 f90441f9044101.gif M1TE&.#EA?`!0`/<```````@("!`0$!@8&"$A(2DI*3$Q,5(`,3DY.5(`.4)" M0E(`0EH`0F,`0DI*2EH`2F,`2E)24EH`4EH(4F,`4FL`4EI:6F,(6F,06F,8 M8V,A8V-C8VL08VLA8T(I:VLA:W,0:W,0>W,8>V\E;WL8A'LAA(08A(0AA&LI MX2$A`!SI0!SK0!SM0![K0![M1!KI0AS MK0QWK0"$K0"$M0"$O1"$O0",M0",O0"4O0"4QBECI3E>I4I2G$I:G"%KI2![ ML2&,O3&.PU)2G%I.G(1CG(1KH(1SK81[K81[M82$M0" MS"V]WC'&WCS#WDW)Y6NWH3>[Y3>[YS>[];>[][> M[^_>[^?GYZ7G[ZWG[];G[][G[Y3G][7G]][G]_?G]^_O[[WO]\;O]\[O]];O M]][O]^?O]^_O]_?O]][O_^_O_];W]^_W]_?W]];W_][W_^?W_^_W__?W___W M_\;__];__^____?______RP`````?`!0```(_@#_"1Q(L*#!@P@3#J1'D-VS M/7'6-''R!,R8-W?\D)LWT)_"CR!#BAQ)\B,T.4F"#"&2A&7+ETDLDFG3IUW) MFSASZC3X:N60)$"#OF1)I.B0)F.2MD&G;Z?3IU`%_B+R4^C0)%?FX`E5JFNH M/'CBV!$#1LVZCE'3JD6XSDJ0H"Y?P@F%2A:J4WCSQCJ%:M8[=';`V!'8=*UA MM<[>`HW+$L\I67A-F3HE>=7DRZ9"$=I`_HOFCSGP,_G,':L$1H4=Q>,42BR8U+/"`"ZW\XU&#((JD MC1-"$84'9)/!LLLD&1PP`1>PG&5@B#0FQ`X95K7DG62GZ*))!@DPT(,NIFSC M88U((O0&&$0M9@4JDYU23`\,+$"!)[J(,DR27!H$SA@EMA0E++&PP,`#&E@X M69=L#J3&&-PI080<4%J(P0,,9*`+9:&($]J';=;XS1A/A'G7>1D\\``&:E(6 M*)MLD-&$2RS-`:4N'2C*@">Q7);,HURR,X89<;4$I2T]+"`!`UL0>8HJ_J&X M`VJ2?9`!YE!7R!++)`Q(\(">K*TY*Y)JV,J8'J?L,L$#JS;2*66FR#)LC?>, M00:30NVWA:H/7+"G*:I0)NVT(7Y9!AAP6:'KG10\H(6KIE@V;EJ`DJM0'Z,6 M*I$RJ8N] MPL/,7W1J&1K)\H[H5$CY&LMU#W[**Z7,;43"CAP>@24+#`)($_.Y[;)I\2CD+L M>6V0,B*(/7NQXKN<1!$-B)ZB1!:QRW3J9J88QC;G#4^#",Q[*("TYIO!$*%:H0D]DYE,'(4$),BB0=72N M91N#`?I6-23*/"M<_B;4#V:")8JX=:0IE$B!(V@HD#0PCWE4$QW6?,6IZE'/ M9M8#XF6*B)!WI"`%KF#B/[3A,S)PT(Q@@$$#I/<`%`3C;:R!G]M(>+I0(&,@ M"?J'(UJ@`N$ASHG]0U@27`#"56VA4XB,DMM,AYDBH84@FTA!"QZQCXO-CHR* M(]\1$,$!1:UJ$A"+HP^#!:U0W,*/35%&"@QA`FC(2(QM>*++R#`$*A`B!YU\ M0`(F08O34>]TL2G%+&RB.8)(HP0MF.0?DH>X\.5M:DT8PA0&D8@6C.`""^@" MD23#S)Y?A^%H:'0L&@A\B!2DNP"&"(!!B+*.@@<#`$/MS&DNNTE?C, M*`8@#.$(-AB$1"7:@A0<`A*X*%!!W($+2!A"DN0*J0-[D3C$(:` MA"CD@)[G5&E156#41)B5K"=H@4H%,0@;%`$)5;6J0NC0N:G!Z:%#D,$.!B&( MH::4J(`]YR#:2H6?8(,P=6?>H$-8#F'^=0*F]!XH_C# M(`ZQB$<\DFM4(B2=\"^)/Z(``%P#)``(P(I!TN(7?^08-IYQ0AP```G3Z`8T M.+$!`$#D(AOYQ/]@A9&7+(`<;V#)1HX`05H,92+38"#'$$"58^P+@?!XRT0> M@$``X`"!>(,`8`;`_B@$DHDT!X`>S9"$`B0QY`$,@`!WSC,!`K#F:Q`9SX#. M,Y$%XH,_Z_G.1-Z`0!`0XT`#FLB9^`<]#.WH`1"Y0#P^=*`'H(`Q$V#,`-!T MG@6PWF/\N=)X+H"D+;!?``@`))T`@"00PN,7H]G'!@'`I_\QZ(,T`P"=]@4` M%'T0&@!@O3S&=4)T/68#@.0'`.@$2,[ABTFK^B.QEG:Q7?P/-$NW(,SF-0`0 MX@TR_Z,6`+A!,PR```6TN]U$?G&M8;QKVT0/Y=9V#XH=)6U/>^/++S,(+E!FCNM\(`G)-9K/HC!V;N- M<(0L?-P'26\?O1* M,.0ZVI4.@*\I.PT^U?+:1ZSF/\AB30# MH.[03O.L"^*-473"\9#'.LJ.@77'8SW'UU"Q07S1#($ -----END PRIVACY-ENHANCED MESSAGE-----